Liver Failure - Pipeline Review, H1 2014

  • February 2014
  • -
  • Global Markets Direct
  • -
  • 71 pages

Liver Failure - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Liver Failure - Pipeline Review, H1 2014’, provides an overview of the Liver Failure’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Failure and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Failure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Liver Failure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Liver Failure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Liver Failure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Liver Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Liver Failure - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Liver Failure Overview 7
Therapeutics Development 8
Pipeline Products for Liver Failure - Overview 8
Pipeline Products for Liver Failure - Comparative Analysis 9
Liver Failure - Therapeutics under Development by Companies 10
Liver Failure - Therapeutics under Investigation by Universities/Institutes 12
Liver Failure - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Liver Failure - Products under Development by Companies 16
Liver Failure - Products under Investigation by Universities/Institutes 17
Liver Failure - Companies Involved in Therapeutics Development 18
Silence Therapeutics plc 18
Digna Biotech, S.L. 19
Ventria Bioscience 20
Conatus Pharmaceuticals Inc. 21
Pharmicell Co., Ltd. 22
Alfact Innovation 23
Immune Pharmaceuticals, Inc. 24
Liver Failure - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 29
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
emricasan - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
ALF-5755 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Livercellgram - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Umbilical Cord Mesenchymal Stem Cell Transplantation - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
cardiotrophin-1 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
GRI-0621 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
EP-1013 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Hepatocytes for Liver Failure - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
EP-1013 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
TAT-ARC - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
Chimeric Fusion Protein - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Small Hairpin RNAs - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
MicroRNA-221 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Immunesafe - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Drug For Liver Diseases - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Optibumin Biosimilar - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Liver Failure - Recent Pipeline Updates 59
Liver Failure - Dormant Projects 63
Liver Failure - Product Development Milestones 64
Featured News and Press Releases 64
Nov 27, 2013: NICE seeks more information on treatment for potentially serious liver condition 64
Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting 64
Apr 02, 2013: ALF-5755 phase II completion 65
Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury 65
Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure 66
Sep 21, 2011: Digna Biotech Receives FDA Orphan Drug Status For Cardiotrophin-1 For Acute Liver Failure Treatment 67
May 06, 2011: ALF-5755 phase II extends to germany 68
May 05, 2011: Alfact Innovation Receives Orphan Drug Designation For ALF-5755 From FDA 68
Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I 68
Mar 10, 2011: Digna Biotech And Biotecnol Announce Spanish Approval For Phase I Clinical study Of Cardiotrophin I 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 71
Disclaimer 71

List of Tables

Number of Products under Development for Liver Failure, H1 2014 8
Number of Products under Development for Liver Failure - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Liver Failure - Pipeline by Silence Therapeutics plc, H1 2014 18
Liver Failure - Pipeline by Digna Biotech, S.L., H1 2014 19
Liver Failure - Pipeline by Ventria Bioscience, H1 2014 20
Liver Failure - Pipeline by Conatus Pharmaceuticals Inc., H1 2014 21
Liver Failure - Pipeline by Pharmicell Co., Ltd., H1 2014 22
Liver Failure - Pipeline by Alfact Innovation, H1 2014 23
Liver Failure - Pipeline by Immune Pharmaceuticals, Inc., H1 2014 24
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Stage and Target, H1 2014 28
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 33
Number of Products by Stage and Molecule Type, H1 2014 35
Liver Failure Therapeutics - Recent Pipeline Updates, H1 2014 59
Liver Failure - Dormant Projects, H1 2014 63

List of Tables

Number of Products under Development for Liver Failure, H1 2014 8
Number of Products under Development for Liver Failure - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Liver Failure - Pipeline by Silence Therapeutics plc, H1 2014 18
Liver Failure - Pipeline by Digna Biotech, S.L., H1 2014 19
Liver Failure - Pipeline by Ventria Bioscience, H1 2014 20
Liver Failure - Pipeline by Conatus Pharmaceuticals Inc., H1 2014 21
Liver Failure - Pipeline by Pharmicell Co., Ltd., H1 2014 22
Liver Failure - Pipeline by Alfact Innovation, H1 2014 23
Liver Failure - Pipeline by Immune Pharmaceuticals, Inc., H1 2014 24
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Stage and Target, H1 2014 28
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 33
Number of Products by Stage and Molecule Type, H1 2014 35
Liver Failure Therapeutics - Recent Pipeline Updates, H1 2014 59
Liver Failure - Dormant Projects, H1 2014 63

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Amitiza (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Amitiza (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • December 2014
  • by Global Data

Amitiza (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel ...

Linzess (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Linzess (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • December 2014
  • by Global Data

Linzess (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel ...

Lotronex (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Lotronex (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • December 2014
  • by Global Data

Lotronex (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel ...


Download Unlimited Documents from Trusted Public Sources

Hospital Industry in the UK

  • February 2015
    6 pages
  • Hospital  

    Asthma  

  • United Kingdom  

View report >

Pathology Description in New Zealand

  • January 2015
    52 pages
  • Cancer  

    Diabetes Mellit...  

    Cardiovascular ...  

  • New Zealand  

    Asia  

    Europe  

View report >

Pathology Description in New Zealand

  • January 2015
    52 pages
  • Cancer  

    Diabetes Mellit...  

    Cardiovascular ...  

  • New Zealand  

    Asia  

    Europe  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.